Skip to content
approvedCognitive & Neuro

Taltirelin

Also known as: Ceredist, TA-0910, Taltirelin Hydrate

Taltirelin (Ceredist) is a synthetic thyrotropin-releasing hormone (TRH) analog approved in Japan since 2000 for the treatment of spinocerebellar degeneration (SCD). Unlike native TRH, which has a half-life of only minutes and strong endocrine effects, taltirelin was engineered with modifications that dramatically extend its duration of action and shift its pharmacological profile toward CNS-specific neuromodulatory effects. It is one of the few approved therapies targeting cerebellar ataxia, a condition with extremely limited treatment options.

3 cited references·5 researched benefits

Quick Answer

Taltirelin (Ceredist) is a TRH analog approved in Japan for spinocerebellar degeneration. It selectively enhances cerebellar neurotransmission without the strong thyroid-stimulating effects of native TRH, improving ataxia symptoms including gait disturbance, speech difficulties, and limb coordination. With an oral half-life of approximately 8 hours, taltirelin is taken as a 5 mg tablet twice daily. Clinical trials in Japan demonstrated significant improvement in ataxia rating scales compared to placebo.

Key Facts

Mechanism
Taltirelin activates TRH receptors (TRH-R1 and TRH-R2) in the central nervous system, particularly in the cerebellum, brainstem, and spinal cord. Its neuromodulatory effects include enhancement of noradrenergic, serotonergic, and cholinergic neurotransmission in cerebellar circuits. Specifically, it facilitates Purkinje cell firing and modulates the excitatory/inhibitory balance in cerebellar cortical circuits. The molecule features a cyclohexylcarbonyl modification at the pyroglutamyl position and a methyl group at the histidyl position, conferring resistance to pyroglutamyl aminopeptidase and prolyl endopeptidase degradation. These modifications reduce its TSH-releasing potency to 1/100th of native TRH while maintaining 10-30 times greater CNS activity.
Research Status
approved
Half-Life
~8 hours
Molecular Formula
C₁₆H₂₃N₅O₄
Primary Use
Cognitive & Neuro
Table of Contents

Benefits

  • Improvement in cerebellar ataxia — significant improvements in ICARS (International Cooperative Ataxia Rating Scale) scores in Japanese clinical trialsstrong
  • Improved gait and balance — patients show measurable improvement in tandem gait, standing stability, and walking speedmoderate
  • Speech improvement — dysarthria (slurred speech) improves in a subset of patients with cerebellar-type speech dysfunctionmoderate
  • Neuroprotective potential — preclinical data suggest TRH analogs may protect cerebellar neurons from degeneration via neurotrophic signalingpreliminary
  • Minimal endocrine effects — dramatically reduced TSH/thyroid stimulation compared to native TRH allows long-term CNS-targeted usestrong

Dosage Protocols

RouteDosage RangeFrequencyNotes
Oral tablet5 mgTwice daily (morning and evening)Standard approved dose in Japan. Taken after meals. Total daily dose is 10 mg. Treatment response is typically assessed over 4-8 weeks. Long-term treatment is generally well-tolerated. Dose adjustments may be needed in patients with hepatic or renal impairment.
Oral tablet (titration)5 mgOnce daily for first week, then twice dailySome clinicians start with once-daily dosing to assess tolerability before increasing to the standard twice-daily regimen. This is not officially mandated but may reduce initial GI side effects.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Nausea and stomach discomfort — the most commonly reported adverse effect, occurring in 5-10% of patientscommon
  • Flushing and feeling of warmth — transient vasodilatory effect similar to TRH, typically mildcommon
  • Mild headache — reported in a small percentage of patients, usually transientcommon
  • Elevated thyroid function — while minimized compared to TRH, some patients may experience mild TSH elevation requiring thyroid monitoringrare
  • Hypersensitivity reactions — rare allergic responses including rash and pruritusrare

Frequently Asked Questions

Is taltirelin available outside of Japan?
Taltirelin (Ceredist) is currently approved only in Japan for spinocerebellar degeneration. It has not been submitted for FDA or EMA approval due to the small market size and the difficulty of conducting large-scale trials in rare cerebellar ataxias. Some patients outside Japan access it through international pharmacies, compassionate use programs, or research chemical suppliers, though quality and legality vary by jurisdiction.
How does taltirelin differ from native TRH?
Native TRH (protirelin) has a plasma half-life of only 5-6 minutes and potently stimulates TSH release from the pituitary, causing thyroid hormone elevation. Taltirelin was engineered with chemical modifications that extend its half-life to approximately 8 hours (enabling oral dosing) and reduce its TSH-releasing potency to about 1/100th of native TRH, while maintaining 10-30 times greater CNS neuromodulatory activity. This allows chronic oral dosing for neurological conditions without significant thyroid disturbance.
What types of ataxia does taltirelin treat?
Taltirelin is approved for spinocerebellar degeneration, which encompasses several progressive cerebellar ataxias including spinocerebellar ataxia (SCA) types, multiple system atrophy-cerebellar type (MSA-C), and cortical cerebellar atrophy. It is most effective in patients with predominantly cerebellar symptoms (ataxia, dysarthria, nystagmus) rather than those with extensive brainstem or autonomic involvement. It does not halt disease progression but may alleviate specific symptoms.

References

  1. 1
    Taltirelin hydrate (TA-0910): a thyrotropin-releasing hormone analogue with ataxia-improving activity in spinocerebellar degeneration(1998)PubMed ↗
  2. 2
    Clinical effects of taltirelin hydrate on spinocerebellar degeneration: a multi-center, double-blind study(2003)PubMed ↗
  3. 3
    TRH analog taltirelin as a novel therapeutic agent for cerebellar ataxia(2000)PubMed ↗

Latest Research

Last updated: 2026-02-19